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Abstract
Background: Zinc finger and BTB domain-containing protein 12 (ZBTB12) is a predicted transcription factor with
potential role in hematopoietic development. Recent evidence linked low methylation level of ZBTB12 exon1
to myocardial infarction (MI) risk. However, the role of ZBTB12 in the pathogenesis of MI and cardiovascular
disease in general is not yet clarified. We investigated the relation between ZBTB12 methylation and several
blood parameters related to cardio-cerebrovascular risk in an Italian family-based cohort.
Results: ZBTB12 methylation was analyzed on white blood cells from the Moli-family cohort using the Sequenom
EpiTYPER MassARRAY (Agena). A total of 13 CpG Sequenom units were analyzed in the small CpG island located in the
only translated ZBTB12 exon. Principal component analysis (PCA) was performed to identify groups of CpG units with
similar methylation estimates. Linear mixed effect regressions showed a positive association between methylation
of ZBTB12 Factor 2 (including CpG units 8, 9–10, 16, 21) and TNF-ɑ stimulated procoagulant activity, a measure of
procoagulant and inflammatory potential of blood cells. In addition, we also found a negative association between
methylation of ZBTB12 Factor 1 (mainly characterized by CpG units 1, 3–4, 5, 11, and 26) and white blood cell and
granulocyte counts. An in silico prediction analysis identified granulopoiesis- and hematopoiesis-specific transcription
factors to potentially bind DNA sequences encompassing CpG1, CpG3–4, and CpG11.
Conclusions: ZBTB12 hypomethylation is linked to shorter TNF-ɑ stimulated whole blood coagulation time and
increased WBC and granulocyte counts, further elucidating the possible link between ZBTB12 methylation and
cardiovascular disease risk.
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Background
The zinc finger and BTB domain-containing protein 12
(ZBTB12) is a predicted transcription factor belonging
to the big family of methyl-CpG-binding proteins
(MBPs) [1]. ZBTB12 consists of four C-terminal C2H2/
Krüppel-type zinc finger domains predicted to bind to
DNA, and an N-terminal BTB (broad-complex,
tram-track, and bric-a-brac) domain for protein–protein
interactions [2]. ZBTB proteins are described to play a
role in hematopoietic development, differentiation and
lineage fate determination [3], and malignant transform-
ation [4]. Guarrera and colleagues [5] performed a
genome-wide DNA methylation analysis in white blood
cells (WBC) from two European cohorts and identified a
region in ZBTB12 as the top differentially methylated
genomic region in patients with myocardial infarction
(MI) [5]. ZBTB12 hypomethylation was associated with
MI risk, and the association was more pronounced in
cases with shorter time to disease [5]. Despite ZBTB12
is expressed in most human tissues (Human Protein
Atlas available from www.proteinatlas.org), its function
and possible role in MI pathogenesis are still unknown.
In light of ZBTB12’s potential role in hematopoiesis
and MI risk, we investigated the association between
ZBTB12 methylation patterns in the Moli-family cohort
[6] and different blood cell parameters related to coagu-
lation, inflammation, and cardiovascular disease (CVD)
risk including whole blood clotting time, platelet–
leukocyte mixed aggregates, and blood cell counts, pre-
viously suggested as CVD risk factors [6–10].
Results
ZBTB12 is located on chromosome 6 and contains two
CpG islands, both covering the only translated exon of
the gene (EXON1, Fig. 1). Mean and standard deviation
(SD) of methylation levels at the 13 ZBTB12 units stud-
ied are shown in Table 1. To identify possible connec-
tions among the ZBTB12 methylation units studied in
the Moli-family cohort, we run a correlation analysis
among all CpG units included in the study (Fig. 2). Since
we found significant CpG unit inter-correlations, we
conducted a principal component analysis (PCA) aiming
at identifying common underlying components that
could explain the largest part of methylation variability
shared across units. Two main methylation factors
emerged with PCA (Table 1), explaining a large part of
gene methylation variance (86.1%). Factor 1 was character-
ized by high positive loadings of CpGs 3–4, 26, 1, 11, 5,
27, 18–20, and 6, and Factor 2 showed high loadings of
CpGs 9–10, 21, 16, and 8 (Table 1). We first studied the
association of ZBTB12 methylation factors with a number
of classical CVD risk factors, including physical activity,
smoke, hypertension, dyslipidemia, obesity, diabetes, and
alcohol consumption. General characteristics and CVD
risk factor distribution in the analyzed cohort are reported
in Table 2. By studying the association between ZBTB12
methylation and these environmental factors, we observed
that alcohol intake greater than 15 g/day (β = − 0.415, p =
0.0024, pFDR significant) was associated with Factor 2,
while obesity (β = 0.40, p = 0.0053) and leisure-time phys-
ical activity (− 0.155, p = 0.0050) were associated with Fac-
tor 1 only with nominal significance (Table 2).
Then, we used linear mixed effect regression models
to evaluate associations between ZBTB12 methylation
Fig. 1 ZBTB12 structure (chr6:31899617-31901992, GRCh38/hg38 Assembly). Exon1 is indicated by a full blue box (“EXON1”). Two CpG islands are
located in the gene (“CGI1” and “CGI2,” depicted as light and dark green boxes, respectively). CpG islands are defined based on the formula
described by Gardiner–Garden et al. J Mol Biol. 1987;196(2):261–282. ZBTB12 conservation across vertebrates is displayed as blue histograms at the
bottom of the figure using the Vertebrate Multiz Alignment & Conservation (100 Species) UCSC track. Sequenom studied region (chr6: 31899847-
31900326, GRCh38/hg38 Assembly) is depicted as red box
Table 1 Distribution of ZBTB12 factor loadings (N = 342) and
specific CpG unit methylation in the Moli-family cohort
CpG
number
Factor loading Methylation levels
Factor 1 Factor 2 N Mean SD
3–4 0.83 0.03 440 0.37 0.09
26 0.80 − 0.04 453 0.37 0.10
1 0.74 0.16 458 0.35 0.10
11 0.70 0.20 415 0.28 0.14
5 0.58 0.19 419 0.11 0.09
27 0.56 0.10 408 0.43 0.14
18–19–20 0.47 0.12 411 0.71 0.12
6 0.43 − 0.15 450 0.64 0.20
9–10 0.27 0.89 457 0.24 0.07
21 0.23 0.83 458 0.09 0.06
16 0.01 0.80 458 0.17 0.10
8 0.26 0.78 457 0.06 0.03
7 0.11 − 0.34 421 0.63 0.14
PCA resulted in the identification of two factors with eigenvalue > 1. Factor
loadings of the main sites for each factor are highlighted in italics
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and different blood parameters related to coagulation, in-
flammation, and CVD risk, namely unstimulated and
TNFɑ-stimulated coagulation time (along with the result-
ing unstimulated–stimulated delta difference), platelet–
monocyte and platelet–PMN aggregates, and blood cell
counts (see Table 3). We did this through a double ap-
proach, by investigating association with methylation fac-
tors and with single CpG units. Because among the
environmental variables associated with ZBTB12 methyla-
tion, only alcohol and obesity were associated with blood
cell counts at p < 0.1 (data not shown), these variables
were additionally included in the model as covariates to
study the association between ZBTB12 methylation and
blood cell counts (Tables 3 and 5).
We found a significant association between Factor 2 and
TNF-α-stimulated whole blood clotting time, with 16.0%
increase in SD of clotting time for an increase of 1 SD in
Factor 2 (β = 0.160, p = 0.0047; Table 3). The linear associ-
ation between TNF-α-stimulated whole blood clotting
time and Factor 2 was evident below the median (− 0.15)
of adherence to the factor (Fig. 3a). Subjects with low
methylation levels at factor units showed a coagulation
time reduced by about half a minute (Δ-time in Fig. 3a)
compared to those with higher methylation levels. The re-
sults did not significantly change when blood cell counts
were added to the models as covariates.
Among blood cell count association results, WBC
were associated with Factor 1, an association mainly
driven by granulocytes (Table 3). In a similar fashion as
for Factor 2, this association was evident at adherence to
Factor 1 below the median (− 0.05), after which a plateau
was reached (Fig. 3b).
A detailed single CpG unit analysis supported the as-
sociations observed with methylation factors, reporting a
Fig. 2 Correlations among the ZBTB12 CpG units. Heatmap showing ZBTB12 CpG unit inter-correlations. Correlation coefficient is depicted for
each CpG unit pair as color range from red (r = − 0.40) up to green (r = 1). P values of correlations are indicated for each CpG unit pair in the
correspondent box
Table 2 Association between ZBTB12 methylation factors and CVD risk factors
CVD risk factors Associations between methylation factors and phenotypes
Factor 1 Factor 2
N Mean SD N Beta SE p-value Beta SE p value
Age (years) 458 42.80 18.83 342 0.005 0.003 0.696 − 0.001 0.003 0.806
Leisure-time physical activity (MET/day) 449 2.31 1.07 336 − 0.111 0.052 0.035 − 0.066 0.052 0.206
N n % Delta SD p value Delta SD p value
Males 458 236 53.7% 342 0.031 0.105 0.768 − 0.148 0.104 0.157
Ever smokers 458 212 46.2% 342 0.182 0.115 0.113 − 0.024 0.114 0.831
Alcohol (> 15 g/day) 422 93 22.0% 319 − 0.013 0.139 0.925 − 0.415 0.135 0.0024*
Hypertension 456 162 35.5% 341 0.040 0.146 0.783 − 0.186 0.144 0.198
Dyslipidemia 456 191 41.9% 341 0.179 0.116 0.125 − 0.150 0.115 0.193
Obesity 456 93 20.4% 341 0.298 0.145 0.041 0.165 0.145 0.256
Diabetes 458 26 5.7% 342 0.159 0.232 0.495 − 0.003 0.230 0.988
Model adjusted by age and gender as fixed effects and family stratification as a random effect. Significant p values are shown in italics
MET metabolic equivalent of task
*pFDR significant (alcohol, pFDR = 0.043)
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Table 3 Association between ZBTB12 methylation factors and blood cell parameters
N Mean SD Associations between methylation factors and phenotypes
N Factor 1 Factor 2
Beta SE p Beta SE p
Functions
Coagulation time (sec.) 417 395.51 77.66 313 − 0.007 0.052 0.891 0.051 0.052 0.333
TNFɑ-stim. coagulation time (sec.) 417 350.90 72.89 313 − 0.021 0.056 0.709 0.160 0.056 0.0047*
Delta coag. time (basal-TNF) (sec.) 417 44.60 56.53 313 − 0.034 0.052 0.510 0.145 0.052 0.0053*
Platelet-monocyte aggr. (%) 450 7.81 9.06 337 0.107 0.045 0.019 0.005 0.046 0.912
Platelet-PMN aggr. (%) 449 4.43 4.97 336 0.032 0.049 0.509 − 0.016 0.050 0.743
Blood cell count
White blood cells (109/L) 458 6.38 1.48 318 − 0.161 0.054 0.0032* − 0.036 0.055 0.509
Lymphocyte (109/L) 458 2.00 0.58 318 − 0.065 0.056 0.254 − 0.063 0.057 0.271
Monocytes (109/L) 458 0.42 0.17 318 − 0.076 0.052 0.147 0.023 0.053 0.661
Granulocytes (109/L) 458 3.96 1.17 318 − 0.158 0.056 0.0048* − 0.032 0.056 0.567
Platelets (109/L) 458 253.82 61.84 318 − 0.050 0.052 0.335 − 0.044 0.053 0.407
Red blood cells (109/L) 458 4.91 0.51 318 − 0.046 0.049 0.352 0.003 0.049 0.945
Model adjusted by age, gender, and smoking as fixed effects and family stratification as a random effect; additional covariates were added to the model and were
associated to both methylation factors and phenotypes (for blood cell counts, alcohol and obesity). Standardized values of phenotypes and methylation are
reported (beta values reported as standard deviation units). Delta coag. time is obtained by the difference between unstimulated and TNFɑ-stimulated coagulation
time. Significant p values are shown in italics
*pFDR significant
Fig. 3 Whole blood clotting times and white blood cell counts by Factor methylation levels. a Whole blood clotting times by Factor 2 methylation
levels: basal (blue, solid line) and TNF-ɑ-stimulated (red, dashed line) whole blood coagulation times and their difference (Delta = basal
minus stimulated; green, dash-dot line). b Count of white blood cell (WBC) populations by Factor 1 methylation levels: WBC (blue, solid
line) and sub-populations of granulocytes (red, short-dashed line), lymphocytes (green, dot-dashed line), and monocyte (brown, long-dashed line). A
local regression with a scatterplot smoothing method that automatically determines the optimal smoothing parameter was used (PROC SGPLOT with
LOESS statement in SAS). Local regression method implies that statistical power decreases at extreme x values (larger confidence intervals)
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significant positive association (pFDR < 0.05) between
Factor 2 single CpG units (CpG8, 9–10, and 16) and
TNF-α-stimulated whole blood clotting time (Table 4).
When adjusting these associations for blood cell counts,
the results did not change.
Furthermore, we observed significant inverse asso-
ciation between Factor 1 single CpG units and dif-
ferent blood cell counts, including WBC (with
CpG1, 3–4, 5, 26, and 11; p ≤ 0.018) and granulo-
cytes counts (with CpG1, 3–4, 5, 26, and 27; p ≤
0.007) (Table 5).
DNA methylation changes at even only one CpG site can
affect transcription factor (TF) binding to the DNA, influ-
encing gene expression. Therefore, we searched for TF pu-
tative binding sites encompassing the WBC significantly
associated ZBTB12 CpG sites. We found several TFs
Table 4 Association between ZBTB12 CpG-specific methylation and blood cell functional parameters
Factor
n.
CpG
n.
Coagulation time TNFɑ-stim. coagulation
time
Delta coag. time
(basal-TNF)
Platelet–monocyte
aggregates
Platelet–PMN
aggregates
Beta SE p Beta SE p Beta SE p Beta SE p Beta SE p
F1 3–4 0.018 0.045 0.690 − 0.019 0.050 0.711 − 0.040 0.049 0.411 0.074 0.039 0.061 0.006 0.043 0.898
26 − 0.007 0.044 0.877 − 0.052 0.049 0.286 − 0.062 0.048 0.201 0.097 0.039 0.013 − 0.003 0.043 0.942
1 0.023 0.045 0.608 0.038 0.049 0.447 − 0.002 0.048 0.974 0.055 0.039 0.164 − 0.023 0.043 0.602
11 0.109 0.046 0.018 0.074 0.051 0.148 − 0.063 0.051 0.218 0.016 0.041 0.703 − 0.016 0.046 0.735
5 − 0.031 0.046 0.501 0.013 0.050 0.798 0.066 0.049 0.179 0.068 0.042 0.102 0.067 0.046 0.142
27 − 0.040 0.047 0.402 − 0.017 0.052 0.743 0.020 0.052 0.704 0.087 0.042 0.040 0.041 0.046 0.366
18–20 0.033 0.044 0.461 0.045 0.048 0.353 − 0.005 0.048 0.912 0.037 0.039 0.342 0.030 0.044 0.496
6 − 0.043 0.044 0.331 − 0.063 0.048 0.191 − 0.004 0.047 0.932 0.026 0.039 0.502 − 0.052 0.043 0.227
F2 9–10 0.104 0.044 0.018 0.154 0.048 0.002* 0.052 0.048 0.274 0.028 0.039 0.478 0.003 0.043 0.951
21 0.030 0.046 0.505 0.045 0.050 0.368 0.014 0.049 0.771 0.036 0.040 0.369 − 0.008 0.044 0.863
16 0.052 0.043 0.224 0.134 0.047 0.005* 0.106 0.046 0.023 − 0.012 0.038 0.757 − 0.010 0.043 0.820
8 0.075 0.044 0.091 0.126 0.048 0.010* 0.061 0.047 0.197 0.031 0.040 0.438 0.019 0.044 0.669
7§ − 0.008 0.046 0.859 − 0.069 0.050 0.169 − 0.086 0.046 0.062 − 0.050 0.041 0.230 − 0.039 0.044 0.380
Model adjusted by age, gender, and smoking as fixed effects and family stratification as a random effect; additional covariates were added to the model and were
associated to both methylation factors and phenotypes (for blood cell counts, alcohol, and obesity). Standardized values of phenotypes and methylation are
reported (beta values reported as standard deviation units). Significant p values are shown in italics
*pFDR significant
§Factor loading for both Factor 1 and 2 lower than 0.40
Table 5 Association between ZBTB12 CpG-specific methylation and blood cell counts
Factor
no.
CpG
no.
White blood cells Lymphocytes Monocytes Granulocytes Platelets Red blood cells
Beta SE p Beta SE p Beta SE p Beta SE p Beta SE p Beta SE p
F1 3–4 − 0.110 0.046 0.018* 0.007 0.047 0.879 0.002 0.043 0.972 − 0.143 0.048 0.003* − 0.030 0.043 0.492 0.033 0.040 0.409
26 − 0.139 0.045 0.002* − 0.011 0.047 0.809 − 0.049 0.042 0.253 − 0.166 0.046 0.0004* − 0.086 0.042 0.042 − 0.003 0.039 0.942
1 − 0.115 0.046 0.013* − 0.009 0.048 0.854 0.015 0.044 0.736 − 0.143 0.048 0.003* − 0.062 0.044 0.166 − 0.036 0.040 0.373
11 − 0.120 0.050 0.016* − 0.098 0.052 0.059 − 0.018 0.049 0.710 − 0.101 0.051 0.050 0.007 0.047 0.885 0.004 0.044 0.936
5 − 0.116 0.048 0.016* 0.039 0.050 0.434 − 0.056 0.046 0.219 − 0.151 0.050 0.003* − 0.037 0.045 0.406 − 0.003 0.042 0.947
27 − 0.109 0.048 0.023 − 0.002 0.050 0.967 − 0.007 0.046 0.884 − 0.134 0.050 0.007* − 0.012 0.046 0.801 − 0.015 0.043 0.728
18–20 − 0.012 0.048 0.808 − 0.130 0.049 0.009 − 0.059 0.045 0.190 0.053 0.049 0.281 0.008 0.045 0.866 − 0.076 0.042 0.073
6 0.006 0.047 0.903 0.020 0.048 0.672 − 0.031 0.044 0.485 0.002 0.048 0.960 0.042 0.044 0.341 0.089 0.040 0.027
F2 9–10 − 0.049 0.046 0.291 − 0.026 0.048 0.591 0.027 0.044 0.540 − 0.058 0.048 0.230 − 0.036 0.044 0.413 − 0.006 0.040 0.880
21 − 0.014 0.047 0.766 0.009 0.049 0.856 0.011 0.045 0.814 − 0.029 0.048 0.551 − 0.050 0.045 0.264 − 0.034 0.040 0.400
16 − 0.015 0.046 0.746 − 0.048 0.047 0.314 0.034 0.043 0.434 − 0.006 0.048 0.901 − 0.011 0.043 0.793 0.031 0.040 0.437
8 − 0.055 0.047 0.234 − 0.015 0.048 0.763 0.029 0.044 0.510 − 0.071 0.048 0.142 − 0.004 0.045 0.928 − 0.059 0.040 0.145
7§ − 0.056 0.048 0.238 − 0.076 0.049 0.119 − 0.067 0.044 0.128 − 0.028 0.049 0.576 − 0.013 0.046 0.784 0.004 0.041 0.920
Model adjusted by age, gender, and smoking as fixed effects, and family stratification as a random effect; additional covariates were added to the model and
were associated to both methylation factors and phenotypes (for blood cell counts, alcohol, and obesity). Standardized values of phenotypes and methylation
are reported (beta values reported as standard deviation units). Significant p values are shown in italics
*pFDR significant
§Factor loading for both Factor 1 and 2 lower than 0.40
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predicted to bind CpG units 1, 3–4, 5, 11, 26, and 27
(Additional file 1). Interestingly, among the putative
transcription factors identified, we observed a high
predictive binding score of PAX-5 and p53 on both
CpG units 1 and 3–4, and of E2F-1 on both CpG
units 3–4 and 11 (Fig. 4).
Discussion
Our study shows that the ZBTB12 methylation profile is
associated with whole blood coagulation time after TNF-ɑ
stimulation and with WBC and granulocyte counts.
ZBTB12 is a highly conserved gene among species, but
still poorly investigated. Recently, its hypomethylation
has been associated with MI risk, in two European co-
horts by Guarrera and colleagues [5]. In our study, we
identified common linking patterns of the 13 ZBTB12
CpG units investigated (Factor 1 and Factor 2 in Table 1)
that independently affect different CVD-related blood
cell characteristics.
On the one hand, ZBTB12 Factor 2 was signifi-
cantly associated with both the TNF-ɑ-stimulated pro-
coagulant activity and the time difference between
unstimulated and TNF-ɑ-stimulated procoagulant ac-
tivity, independently on blood cell counts. Reflecting
blood procoagulant activity potential, the coagulation
time is calculated as the time taken for recalcified
blood to clot and is considered to be a sensitive
marker of the potential clot formation and CVD risk
[7]. This is because thrombus formation depends
upon the procoagulant and inflammatory potential of
blood cells, including monocytes, granulocytes, plate-
lets, endothelial cells, and plasma vesicles [11]. TNF-ɑ
is specifically implicated in inflammation-related
thrombosis by promoting extrinsic coagulation activa-
tion. This is achieved by inducing tissue factor ex-
pression on the leukocyte surface, downregulating
natural anticoagulants (protein C and heparin–
antithrombin pathways) as well as thrombomodulin
and the endothelial protein C receptor, while increas-
ing platelet production, thereby enhancing thrombin
formation [12].
On the other hand, ZBTB12 Factor 1 hypomethylation
is associated with higher total WBC and granulocyte
counts already having been associated with higher CVD
risk and mortality [8, 9]. Neutrophils, the largest part of
granulocyte population, are also involved in the forma-
tion of neutrophil extracellular traps (NETs), known to
play a role in thrombus formation [13]. Both white and
red blood cells contribute to the activation of coagula-
tion and to thrombin formation also through the action
of their extracellular vesicles (EVs), additional mediators
of inflammation [14]. These results suggest a second po-
tential role of ZBTB12 in affecting myelopoiesis.
ZBTB12 expression could be regulated through the
binding of myelopoiesis and hematopoiesis-specific TFs,
also influenced by DNA methylation [15]. In line with this
hypothesis, our data on ZBTB12 TF binding site predic-
tion showed that the ZBTB12 CpG units 1, 3–4, and 11
are predicted to be bound by PAX-5 and p53 (units 1 and
3–4), known to be involved in hematopoiesis and B cell
differentiation [16] and cell cycle arrest required for ter-
minal myelopoiesis [17, 18], and by E2F-1 (units 3–4 and
11), with a pro-apoptotic role in hematopoiesis [19]
(Fig. 4). Supporting this hypothesis, ZBTB12 expression in
blood cells is indeed variable across cell types and differ-
entiation stages (data from the BLUEPRINT Consortium
[20], https://blueprint.haem.cam.ac.uk/mRNA). ZBTB12,
as all ZBTB proteins, could also in turn bind
myelopoiesis-related genes, acting as a TF, thanks to its
predicted ability of binding methylcytosine (5mC) and/or
oxidized methylcytosine (oxi-mCs)-rich DNA sequences,
target sequences for Zn fingers [3]. DNA methylation is a
known predictor of cell specification throughout the hu-
man hematopoietic lineage [21], and other ZBTB proteins
Fig. 4 Prediction binding site analysis of ZBTB12 transcription factors. PROMO/TRANSFAC Transcription Factor Prediction analysis on ZBTB12 sequences
including a CpG1, b CpG3–4, c CpG11. The length of each box indicating the transcription factor identifies its predicted binding sequence. The number
into each box identifies the specific transcription factor (0 = PAX-5; 1 = p53; 2 = TFII-I; 3 = c-Ets-1; 4 = STAT4; 5 = Elk-1; 6 = XBP-1; 7 = GCF; 8 = E2F-1)
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are already described to be specifically involved in granu-
lopoiesis [22] and myeloid development in general [23].
Conclusion
Our data indicate that ZBTB12 hypomethylation (of
both Factor 1 and Factor 2) that was previously asso-
ciated with MI risk [5] is linked to shorter TNF-ɑ-sti-
mulated whole blood coagulation time and increased
WBC and granulocyte counts. This hitherto unde-
scribed association with blood parameters, known to
be implicated in CVD [7–9], further support the hy-
pothesis of a link between ZBTB12 methylation and
CVD risk. Future experimental studies should focus
on the specific molecular mechanism(s) of this zinc
finger protein in blood cell proliferation, maturation,
and activity and its possible role in human cardiovas-
cular disorders.
Methods
Study population
Moli-family is a family-based study which aimed to in-
vestigate the role of inflammation-mediated activation of
hemostasis in CVD risk [6]. A total of 754 subjects (≥
15 years old) were recruited from 54 extended pedigrees
(23 families with and 31 control families without per-
sonal or familial history of early-onset MI). All partici-
pants were relatives of index subjects enrolled in the
Moli-sani cohort study [24], which recruited 24,325 sub-
jects randomly selected from civil registries of the Mo-
lise Region, Southern Italy, between 2005 and 2010.
In all subjects, a complete medical history and infor-
mation about smoking and alcohol-drinking habits were
obtained via a structured questionnaire. Height, body
weight, and blood pressure were measured as described
in [6, 25, 26].
Blood sample collection and blood functional tests
Biochemical analyses were performed in the centralized
Moli-sani laboratory. Blood samples were obtained be-
tween 07:00 and 09:00 from participants who had fasted
overnight and had refrained from smoking for at least 6
h. Hematological cytometric analyses were performed by
the same cell counter (Coulter HMX, Beckman Coulter,
IL Milan, Italy), within 1 h from venipuncture. Platelet–
leukocyte conjugates, platelet P-selectin, leukocyte
CD11b, and L-selectin expression were measured in
whole blood for the Moli-family participants, as de-
scribed [27].
Whole blood procoagulant activity was measured by
the coagulation time. Whole blood was incubated for 2 h
at 37 °C with or without tumor necrosis factor (TNF)-α
(100 ng/ml). The optimal agonist concentration was pre-
viously selected on the basis of dose-response curves
(not shown). At the end of incubation, whole blood
coagulation time (i.e., the time taken for recalcified
blood to clot) was assessed by a one-stage clotting time.
Briefly, 200-μL whole blood were mixed with 100 μL 25
mM CaCl2, and the time to clot formation was recorded
(seconds) [28].
DNA extraction and methylation analysis
Buffy coats of peripheral blood cells were isolated from
whole blood samples collected in sodium citrate EDTA
tubes and centrifuged at 3000 rpm for 20min at RT.
DNA extraction was done using a silica matrix-based
method as described [29]. Of the 754 Moli-family partic-
ipants, 623 had good quality DNA samples to perform
the methylation analysis. We measured ZBTB12 methy-
lation using the Sequenom EpiTYPER MassARRAY
(Agena) platform [15]. Details of the ZBTB12 region
studied (chr6: 31899847-31900326, GRCh38/hg38 As-
sembly) are reported by Guarrera and colleagues [5]. Bi-
sulfite treatment was conducted on 1 μg of genomic
DNA using the MethylDetector kit (Active Motif ) as de-
scribed [15]. All PCR amplifications were performed in
duplicate. For the CpG-specific analysis, data were dis-
carded when the duplicate measurements had a standard
deviation (SD) ≥ 5% [15, 30, 31]. Sequenom peaks with
reference intensity > 2 and overlapping units were ex-
cluded from the analysis [15, 30, 31]. To exclude pos-
sible intra-plate differences, a sample of K562 DNA was
carried on in each plate as an internal control.
Of the 20 CpG units included in the ZBTB12 region
studied [5] (CGI1 in Fig. 1), we excluded the ones having
more than 15% of missing values in the Moli-family co-
hort, leading to a total of 13 CpG (Table 1).
Statistical analysis
Statistical analyses were performed using SAS/STAT
software (Version 9.4 for Windows©2009. SAS Insti-
tute Inc. and SAS are registered trademarks of SAS
Institute Inc., Cary, NC, USA). Mean and SD were
computed for continuous variables and frequencies
for categorical variables. All continuous variables, in-
cluding methylation data, were also transformed to
z-scores (mean = 0; SD = 1).
Correlation analysis among ZBTB12 CpG units was
initially conducted to discover the architecture of rela-
tionships among the methylation units studied. Then, a
PCA was conducted with the aim of identifying common
underlying patterns that could explain the largest part of
common variance in methylation across units. PCA was
conducted including the 342 individuals having all the
13 ZBTB12 CpG units successfully measured. Criteria
for factor selection were eigenvalue > 1.0 as revealed by
the scree test, and the interpretability of the final solu-
tion. This resulted in the identification of two main fac-
tors (Table 1), which were transformed by the
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orthogonal varimax rotation to keep independent latent
variables for subsequent analysis [32], and then stan-
dardized. We characterized the factors using the
ZBTB12 methylation sites with an absolute factor load-
ing > 0.40. Each subject received a factor score, calcu-
lated by summing the observed methylation site values,
each weighted by factor loadings.
We first studied the association between ZBTB12
methylation factors and CVD risk factors (unstimulated
and TNFɑ-stimulated coagulation time along with the
resulting unstimulated–stimulated delta difference,
platelet–monocyte and platelet–PMN aggregates, and
blood cell counts) (Table 2), in linear mixed effect re-
gression models adjusted for age, sex (fixed effects), and
family stratification (random effect) to account for the
family structure of the Moli-family cohort.
Similarly, linear mixed effect regression models were
used to assess the relation of blood parameters re-
lated to CVD risk, with ZBTB12 methylation patterns
(Factor 1 and Factor 2) and single CpG units. Age,
gender, smoking (never-, ex-, and current smokers),
and variables significantly associated with both methy-
lation factors and specific phenotypes at p < 0.1 were
treated as fixed effects, while family stratification was
treated as a random effect. A false discovery rate
(FDR) method (Benjamini–Hochberg) was used to ad-
just p values for multiple testing. A p value (pFDR) <
0.05 was considered as statistically significant. DNA
methylation is cell specific and might be different
among the leukocyte sub-populations, leading to false
positive findings when an appropriate correction for
cell count is not performed [33]. ZBTB12 was not
identified as a locus with leukocyte-specific DNA
methylation levels [33]. Therefore, in our analysis, we
did not correct for WBC counts.
Prediction of ZBTB12 DNA binding factors
To detect potential regulatory effects of methylation at the
CpG sites investigated, we searched for ZBTB12 putative
binding sites, by using the PROMO software [34]. More
specifically, we included in our query the regions sur-
rounding each of the CpG sites which were found as asso-
ciated with blood cell parameters in previous analyses.
This allows to construct weight matrices from known
binding sites extracted from the TRANSFAC DNA bind-
ing site library (version 8.3), which contains the largest
available collection of DNA binding sites in eukaryotes
[35, 36]. The full ZBTB12 region analyzed in the
methylation study (chr6: 31899847-31900326, GRCh38/
hg38 Assembly) was used as DNA sequence bait in the
search. The prediction was made by focusing only on
the human species and transcription factors, setting the
minimum sequence similarity threshold for TF binding
detection to 85%.
Additional file
Additional file 1: Putative transcription factor (TF) binding analysis of
the blood cell count specific CpG units. Transcription factor predicted to
bind to blood cell count specific CpG units. (DOCX 13 kb)
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